Qyuns Therapeutics Partners with Roche for Global Rights to Long‑Acting Bispecific Antibody QX031N
Qyuns Therapeutics Co., Ltd. (HKG: 2509) today announced a global exclusive collaboration and licensing agreement with F. Hoffmann‑La...
Jiangsu Aidea Secures Approval to Launch ADC118 Tablets in China, First Domestic HIV Integrase FDC
Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced today that its self‑developed Class 1 anti‑HIV drug, ADC118...
Fosun Pharmaceutical Q3 2025 Revenue Slips 5.5% Amid VBP, Innovative Drugs Grow 18%
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today released its third‑quarter 2025 financial results....
Junshi Biosciences Q3 2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today released its third‑quarter 2025 financial results....
Fosun Pharmaceutical Announces Spin‑Off and HK Listing of Adgenvax
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today disclosed its intention to spin‑off...
Fosun Pharma Target Fund Launches with RMB 1 Billion Capital, Led by China Resources GP
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its controlled subsidiary,...
Alphamab Oncology Secures FDA Fast‑Track Designation for HER2 Bispecific ADC JSKN003 in Platinum‑Resistant Ovarian Cancer
China‑based Alphamab Oncology (HKG: 9966) announced today that the U.S. Food and Drug Administration (FDA)...
SSY Group Limited Projected to Win 12 Products in China’s Eleventh VBP Round
China‑based SSY Group Limited (HKG: 2005) announced today that it has been pre‑selected as the...
Hengrui Pharmaceuticals Secures NMPA Acceptance for Fluzoparib in First‑Line Therapy of DNA‑Repair‑Defect Positive mCRPC
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the China National...
Nanjing Leads Biolabs Announces First‑Patient Dose of LBL‑024, a Novel Bispecific Antibody for Biliary Tract Cancer
China‑based Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the first patient has...
Eisai and Merck Present 5‑Year Survival Data for Lenvatinib‑Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025
At the European Society for Medical Oncology (ESMO) 2025 Congress, Eisai (TYO: 4523) and Merck,...
PolyMed Biopharmaceuticals Completes Pre‑A++ Funding Round Led by Caleb Capital, Fuels PROTAC‑Focused Pipeline
PolyMed Biopharmaceuticals Co., Ltd., a Chinese‑based, internationally‑oriented biopharma innovator, announced the successful closure of its...
NMPA Releases Draft Measures on Drug Quality Sampling, Seeks Public Comments by Nov 5
The National Medical Products Administration (NMPA) today issued the “Measures for the Administration of Drug...
Novartis Asciminib Enters China’s SPARK Program for Pediatric Chronic Myeloid Leukemia
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced today...
WuXi AppTec Sells WuXi Clinical and MedKey to Hillhouse for RMB 2.8 Billion
WuXi AppTec (Shanghai) Co., Ltd., a wholly‑owned subsidiary of Wuxi AppTec Co., Ltd. (SHA: 603259,...
Wuxi Apptec Reports 15.3 % YoY Revenue Growth in Q3 2025, Net Profit Hits RMB 4.22 Billion
Wuxi Apptec Co., Ltd. (SHA: 603259, HKG: 2359) today announced third‑quarter 2025 financial results, delivering...
Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based company, announced on October 26, 2025, that...
Novartis Strikes USD 12b Deal for Avidity’s RNA Therapeutics and Gene-Targeted Pipeline
Novartis (NYSE: NVS) announced an agreement to acquire San Diego-based biotech Avidity Biosciences for USD...
Eli Lilly to Acquire Adverum Biotechnologies for Up to USD 261.7m for Ixo-vec Access
Eli Lilly (NYSE: LLY) announced on October 24, 2025, that it will acquire gene therapy...
Alphamab Oncology’s JSKN003 Approved for Phase III Trial in HER2-Positive CRC
Alphamab Oncology (HKG: 9966), a China-based biotechnology company, announced on October 27, 2025, that its...